Alnylam Pharmaceuticals, Inc. (ALNY)
RNAi biopharma with own manufacturing, one pattern. Read November 9, 2026 from the annual report for the period ending December 31, 2025, filed February 12, 2026. Ranked 89 of the 145 Healthcare companies read so far, by the share within reach now.
Within reach now
32%
projected from METR's April 2026 measurement and Epoch's November 2026 index
End of 2028
44%
Employees, annual report
2,500
Leading staffing pattern
Pharmaceutical and Medicine Manufacturing
Share of the working time within reach, long-run pace, four times in five
Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.
- Now32%
- End of 202741%
- End of 202844%
- End of 203044%
What changes for its people by the end of 2028, by its industries' figures
- Stays with people 57%
- Becomes checking a model's work 38%
- Handed over with lighter checks 4%
The filing states approximately 2,500 full-time employees at December 31, 2025, 78% in the U.S., and describes one biopharmaceutical business from research to manufacturing with no count by function, so the whole workforce is read at pharmaceutical manufacturing by description.
The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.
What follows from the reading
Share of working time within reach of AI, on the long-run pace at four in five: 32% now, 41% at the end of 2027, 44% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 14% people work and 42% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 57% of the working time stays with people (conversation, in-person and hands-on work), 38% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.
Headcount
2,500 employees as of December 31, 2025 (stated). Approximately 1,945 of 2,500 employees in the U.S. and 555 outside (stated).
The filing: “As of December 31, 2025, we employed approximately 2,500 full-time employees, of whom approximately 1,945 were employed in the U.S. and approximately 555 were employed outside of the U.S.”
The workforce as industry patterns
| Pattern | Share | Reason, from the filing |
|---|---|---|
| Pharmaceutical and Medicine Manufacturing | 100% | The filing describes a commercial-stage biopharmaceutical company with research, clinical development, medical affairs, commercial and manufacturing functions and a manufacturing facility in Norton, Massachusetts, with no count by function, so the whole workforce is read at pharmaceutical and medicine manufacturing by description (c). |
What the filing says about the workforce: Approximately 2,500 full-time employees at December 31, 2025, about 1,945 in the U.S. and 555 outside, up from 2,230 after about 270 hires in 2025 across commercial, clinical development, research, medical affairs, manufacturing and administrative functions; no U.S. union; more hiring expected in 2026 with the Norton plant expansion.
Companies read with the same leading pattern
Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five. Now is projected from METR's April 2026 measurement and Epoch's November 2026 index.
- Johnson & Johnson (JNJ, 140,800 employees)30% now, 41% by 2028
- Thermo Fisher Scientific Inc. (TMO, 125,000 employees)36% now, 53% by 2028
- Merck & Co., Inc. (MRK, 75,000 employees)32% now, 44% by 2028
- Pfizer Inc. (PFE, 75,000 employees)32% now, 44% by 2028
- AbbVie Inc. (ABBV, 57,000 employees)32% now, 44% by 2028
- Eli Lilly and Company (LLY, 50,000 employees)32% now, 44% by 2028
- Bristol-Myers Squibb Company (BMY, 32,500 employees)32% now, 44% by 2028
- Amgen Inc. (AMGN, 31,500 employees)32% now, 44% by 2028
What the filing says about AI
0 sentences in the filing name AI. The filing names artificial intelligence in no sentence.
Its annual reports, year by year
Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector
- Fiscal 20210median 0
- Fiscal 20220median 0
- Fiscal 20230median 1
- Fiscal 20240median 4
- Fiscal 20250median 10
Headcount by filing year
As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.
| Period | Employees | Filed | Filing |
|---|---|---|---|
| 2025-12-31 | 2,500 | 2026-02-12 | 10-K |
| 2024-12-31 | 2,230 | 2025-02-13 | 10-K |
| 2023-12-31 | 2,100 | 2024-02-15 | 10-K |
| 2022-12-31 | 2,002 | 2023-02-23 | 10-K |
| 2021-12-31 | 1,665 | 2022-02-10 | 10-K |
| 2020-12-31 | 1,453 | 2021-02-11 | 10-K |
| 2019-12-31 | 1,323 | 2020-02-13 | 10-K |
| 2018-12-31 | 1,065 | 2019-02-14 | 10-K |
| 2017-12-31 | 749 | 2018-02-15 | 10-K |
| 2016-12-31 | 514 | 2017-02-15 | 10-K |
| 2015-12-31 | 369 | 2016-02-12 | 10-K |
| 2014-12-31 | 256 | 2015-02-13 | 10-K |
| 2013-12-31 | 165 | 2014-02-20 | 10-K |
| 2012-12-31 | 129 | 2013-02-19 | 10-K |
| 2011-12-31 | 116 | 2012-02-13 | 10-K |
| 2010-12-31 | 172 | 2011-02-18 | 10-K |
| 2009-12-31 | 178 | 2010-02-26 | 10-K |
| 2008-12-31 | 170 | 2009-03-02 | 10-K |
| 2007-12-31 | 129 | 2008-03-10 | 10-K |
| 2006-12-31 | 122 | 2007-03-12 | 10-K |
| 2005-12-31 | 94 | 2006-03-16 | 10-K |
| 2004-12-31 | 71 | 2005-03-30 | 10-K |
Limits of this reading
- The count is of full-time employees; no part-time figure is stated.
- No count by function; the research staff are inside the pharmaceutical pattern because the filing does not count them (c).
Source: the company's annual report on EDGAR, accession 0001628280-26-007497, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.
The report on Alnylam Pharmaceuticals, Inc., $29
This page as a document to keep, with what it does not show: the share within reach at every date on three paces and two reliabilities, a typical workforce of this shape at the stated headcount role by role and task by task (the industries' staffing, never the company's roster), where to start, what changes for the people and what they would learn, every sentence in the filing that names AI, the headcount by year, the companies read with the same leading pattern, the method and a citation line. To print or save as a PDF, open again in your browser for a year.
See the report, $29See the sample first: Walmart's report is free
Questions about this company
- How much of Alnylam Pharmaceuticals, Inc.'s working time is within reach of AI?
- An estimated 32% now and 44% by the end of 2028, on METR's long-run pace at four in five, from the workforce Alnylam Pharmaceuticals, Inc.'s own annual report describes and BLS staffing patterns for its industries, never from a roster. It is an estimate with a stated method. It is not a forecast of jobs lost or of savings, and it says nothing about what the company will do.
- How many people does Alnylam Pharmaceuticals, Inc. employ?
- 2,500 as of December 31, 2025, as its annual report for the period ending December 31, 2025 states. About 78% in the U.S.
- What kinds of work make up Alnylam Pharmaceuticals, Inc.'s workforce?
- Read from its annual report as a blend of 1 industry staffing pattern, the largest Pharmaceutical and Medicine Manufacturing; by those patterns the work is about 44% desk work, 14% people work and 42% body work. Each share has a one-sentence reason on this page that can be checked against the filing.
- What does Alnylam Pharmaceuticals, Inc.'s annual report say about AI?
- 0 sentences in the filing name AI. Its annual reports for fiscal 2021 to 2025 name it in 0, 0, 0, 0 and 0 sentences, year by year. They are counted and quoted on this page, never judged: a count says how much a filing talks about AI, not what the company does with it.
- How is this estimated?
- Claude Fable 5.1 read the annual report under the Index's written rubric (version 1) on November 9, 2026: the stated headcount, the share in the U.S. when stated, and the workforce as a blend of industry staffing patterns. The estimates are the site's industry estimates weighted by those shares, from O*NET tasks with estimated lengths and METR's measurements of how long a task AI models can finish. A company can write to info@stratussc.com to have its reading checked against its filing.
Embed these figures on your site
A small card with the share of working time within reach now and at the end of 2027, 2028 and 2030, the date and a link back. Free under CC BY 4.0; the card carries the credit.